SPiDEM® Platform (Prazer’s approach to TPD)

SPiDEM technology is an innovative technology that differs from existing TPD methods, which ubiquitinate disease-causing proteins by binding them to specific E3 ligases. Unlike conventional TPD technology, where ubiquitination occurs through a specific E3 ligase, in SPiDEM technology, the compound itself undergoes ubiquitination. It has a structure without a linker, resulting in a smaller molecular weight, overcoming the limitations of existing PROTAC technology. Additionally, while existing TPD technology relies on only a specific E3 ligase, SPiDEM technology can receive ubiquitin from various E3 ligases, enabling the degradation of target proteins through both the proteasome and lysosome depending on the characteristics of the target protein. Due to these characteristics, unlike existing TPD technologies, SPiDEM technology can target all intracellular proteins, including nuclear proteins, cytoplasmic proteins, aggregated proteins, and membrane proteins.

Prazer Therapeutics’ goal is to identify and advance new mechanisms to tackle the challenges faced by the previous generations of TPD therapeutics. Prazer’s proprietary TPD platform, selective protein degradation enabling moiety (SPiDEM), allows the rational design and rapid optimization of orally available and BBB-penetrating small molecules. SPiDEM’s novel degrading mechanism has potential for enhanced drug-likeness, expanded therapeutic applications, reduced risk of drug resistance and sustained efficacy.